Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection

The Journal of Antimicrobial Chemotherapy
Christopher J Bruno, Jeffrey M Jacobson

Abstract

The majority of currently available agents for the treatment of HIV-1 infection act by targeting one of several intracellular steps in the viral life cycle. Despite improvements in efficacy and tolerability, the development of viral resistance to these agents is common and significant toxicity and adherence issues still occur. For this reason the development of safe, well tolerated antiviral agents that target a novel step in the viral life cycle remains important. Viral entry into host cells affords several potential extracellular targets for antiretroviral therapy. Ibalizumab, a humanized monoclonal antibody to CD4, the primary host cellular receptor for HIV-1 entry, has been shown to block HIV-1 entry in vitro. Early clinical trials have demonstrated significant antiviral efficacy with a >1 log(10) reduction in viral load when given as monotherapy. Its long half-life, which allows weekly dosing, and its administration as an intravenous infusion differentiate it from other currently available antiretroviral agents. These properties may prove useful in allowing improved drug delivery to patients who have had difficulty adhering to daily oral regimens. Its unique mode of action reduces the risk of cross-resistance with currentl...Continue Reading

References

Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Jan 15, 2004·The Journal of Infectious Diseases·Daniel R KuritzkesWilliam R Shanahan
Feb 9, 2006·The Journal of Antimicrobial Chemotherapy·Verónica BrizVincent Soriano
May 26, 2006·Antimicrobial Agents and Chemotherapy·Xing-Quan ZhangRobert T Schooley
Apr 3, 2009·Current Opinion in HIV and AIDS·Daniel R Kuritzkes

❮ Previous
Next ❯

Citations

May 9, 2012·AIDS Research and Human Retroviruses·Maria F PerdomoAnders Vahlne
Oct 9, 2013·Current Opinion in HIV and AIDS·William R SpreenJohn C Pottage
Sep 1, 2011·Therapeutic Advances in Chronic Disease·Mathias Lichterfeld, Kimon C Zachary
Jun 16, 2012·Indian Journal of Pharmacology·Mira DesaiR K Dikshit
Feb 3, 2016·The Journal of Experimental Medicine·Jean Langhorne, Patrick E Duffy
Jan 31, 2015·Cell·Rachel P GalimidiPamela J Bjorkman
Nov 8, 2011·Infectious Disease Clinics of North America·Jan Ter Meulen
Mar 8, 2011·Trends in Microbiology·Michael Caffrey
Dec 21, 2012·Immunological Investigations·Lan LiHao Wu
Jul 22, 2015·The Journal of Experimental Medicine·Zenon A ZenonosGavin J Wright
Aug 20, 2016·Infectious Diseases and Therapy·Melissa E BadowskiJohn A Littler
Nov 22, 2016·International Journal of Molecular Sciences·Zhiqing ZhangNingshao Xia
Dec 13, 2017·Frontiers in Microbiology·Simona A Iacob, Diana G Iacob
Jun 7, 2017·Antimicrobial Agents and Chemotherapy·David WenselJonathan Davis
Oct 25, 2014·Journal of Computer-aided Molecular Design·Yeng-Tseng Wang, Lea-Yea Chuang
Jan 20, 2018·Expert Review of Anti-infective Therapy·Said A Hassounah, Thibault Mesplède
Jun 8, 2015·Current Opinion in HIV and AIDS·David A Margolis, Marta Boffito
May 11, 2018·Current Opinion in HIV and AIDS·Robert L BettikerJeffrey M Jacobson
Dec 12, 2019·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tyler LanmanRonald Ellis
Jan 11, 2019·Molecular Medicine Reports·Emmanuele Venanzi RulloGiovanni F Pellicanò
Oct 23, 2019·Frontiers in Immunology·Korbinian BöslRichard K Kandasamy
Jun 25, 2015·Microbiology Spectrum·Adam Hey
Jun 25, 2015·Microbiology Spectrum·Donald N Forthal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.